Excel in. Intelligence out. · Swiss PSC + DACH
Good morning. Three things to look at this week.
13 KOLs tracked across Switzerland and Germany · 3 signals since your last visit
Total KOLs
13
DACH hepatology
Tier 1
6
National leaders
Rising stars
3
Across tiers · momentum signal
Open gaps
1
Engagement gap detected
Strategic signals
Trend detection · pattern intelligence · leadership view
◆ Topic shift emerging
Microbiome + PSC publications up 47% YoY across DACH
3 new authors emerging — including Dr. N. Schmid (Basel). Recent activity around microbiome + rare hepatology overlap.
Explore topic trend →
● Institution gap
Univ. Basel · 3 high-evidence KOLs · only 1 actively engaged
Müller · active
Huber · dormant
Schmid · untracked
Significant concentration of PSC + PBC expertise unaddressed. Two-thirds of Basel high-evidence KOLs are not currently in active engagement.
Open Basel cluster →
◇ Network bridge
Dr. Schmid bridges Basel ↔ Romandie networks
Co-publishes with Müller (Basel) + Fischer (Geneva). Rare cross-canton connector — engaging early opens both networks.
Open network view →
Tier distribution
13 KOLs across 3 tiers · plus rising stars overlay
Tier 1 · 6
Tier 2 · 4
Tier 3 · 3
Country split
DACH spread · Swiss-heavy, German bench
Switzerland: 9 · Germany: 4
Tier 1 by archetype
6 KOLs
Roster shape · where you have depth vs. gaps
4 Pioneers · 0 Trial Leaders at T1 · single-deep elsewhere
This week
3 signals · pushed by AI
Engagement gap
Prof. Doe (USZ) is not on the Dr Falk roster — leading PSC voice, EASL guideline co-author.
Open profile →
Rising star
Dr. N. Schmid (Basel) — momentum 8.4/10, bridge-builder in Basel-Romandie network.
See rising stars →
Activity
Prof. T. Lindauer (LMU Munich) published in J Hepatol on HCC.
Open citation →
Your roster · top 5
View all 13 →
Name
Specialty
Institution
CC
Tier
Sci
Cli
Inf
Score
Benchmark
Prof. H. ReiterScientific Pioneer
Hepatology, NASH
USZ Zurich
T1
9.5
9.0
9.0
9.2/10 ●●●
Matched
Prof. Dr. med. John DoeScientific Pioneer
PSC, AIH
USZ Zurich
T1
8.5
9.0
8.0
8.5/10 ●●●
Missing
Dr. A. MüllerScientific Pioneer
Hepatology, PBC
Univ. Basel
T1
9.0
8.5
8.0
8.5/10 ●●●
Matched
Prof. T. Lindauer ★Scientific Pioneer
HCC, Portal HT
LMU Munich
T1
8.6
8.8
8.2
8.5/10 ●●●
Matched
Prof. E. HuberGuideline Author
Autoimmune liver
Univ. Basel
T1
8.5
8.0
8.5
8.3/10 ●●●
Dormant
Excel in. Intelligence out. · DACH hepatology
KOL roster
13 KOLs · sorted by composite score · click any row to open profile · evidence confidence ●●● inline next to score
Name
Specialty
Institution
CC
Tier
Sci
Cli
Inf
Score
Benchmark
Prof. H. ReiterScientific Pioneer
Hepatology, NASH
USZ Zurich
T1
9.5
9.0
9.0
9.2/10 ●●●
Matched
Prof. Dr. med. John DoeScientific Pioneer
PSC, AIH
USZ Zurich
T1
8.5
9.0
8.0
8.5/10 ●●●
Missing high-priority
Dr. A. MüllerScientific Pioneer
Hepatology, PBC
Univ. Basel
T1
9.0
8.5
8.0
8.5/10 ●●●
Matched
Prof. T. Lindauer ★Scientific Pioneer
HCC, Portal HT
LMU Munich
T1
8.6
8.8
8.2
8.5/10 ●●●
Matched
Prof. E. HuberGuideline Author
Autoimmune liver
Univ. Basel
T1
8.5
8.0
8.5
8.3/10 ●●●
Dormant
PD Dr. K. SchusterSociety Influencer
Hepatology
Inselspital Bern
T1
8.0
7.5
7.0
7.5/10 ●●○
Dormant
Dr. S. BaumannPractitioner
Gastroenterology
CHUV Lausanne
T2
7.5
7.0
7.5
7.3/10 ●●○
Dormant
Dr. K. MühlbauerTrial Leader
PSC, IBD-related
Univ. Frankfurt
T2
7.5
6.9
7.1
7.2/10 ●●○
Priority mismatch
Dr. R. SteinmannTrial Leader
Cirrhosis, Transplant
Klinikum Stuttgart
T2
6.8
7.4
6.9
7.0/10 ●●○
Dormant
Dr. L. Fischer ★Rising Star
Gastroenterology
HUG Geneva
T2
6.5
6.0
6.5
6.3/10 ●●○
Emerging untracked
Dr. M. BernasconiPractitioner
Gastroenterology
Lugano (Private)
T3
5.0
5.5
6.0
5.5/10 ●●○
Matched
Dr. T. BrunnerPractitioner
Gastroenterology
Kantonsspital Aarau
T3
5.5
5.0
5.5
5.3/10 ●○○
Data quality
Dr. N. Schmid ★Rising Star
PSC, Gut Microbiome
Univ. Basel
T3
4.8
5.5
5.0
5.1/10 ●○○
Emerging untracked
Predictive · DACH hepatology
Rising stars
3 KOLs with accelerating momentum · flag sits independently of tier
Rank 1 · high potential
Dr. N. Schmid
Univ. Basel · T3 today · PSC + Gut Microbiome
8.4/10
± 0.6 confidence
Publication velocity 3.8× baseline · co-authored 2 papers with Prof. Kessler (Basel) · acts as network bridge to Romandie cluster · composite 5.1 today with strong upward trajectory.
Rank 2 · emerging at T1
Prof. T. Lindauer
LMU Munich · T1 today · HCC + Portal HT
7.2/10
± 0.4 confidence
Already T1 but momentum signal continues · J Hepatol senior author 3 days ago · anchors German hepatology network · candidate to lead DACH expansion strategy.
Rank 3 · emerging
Dr. L. Fischer
HUG Geneva · T2 today · Gastroenterology
6.8/10
± 0.8 confidence
Romandie-based · 3 PBC publications in 18 months · no EFPIA disclosures · fills the geographic gap on the current roster. Composite 6.3 today, momentum +22 last quarter.
How we calculate momentum
Methodology · audit-ready
Momentum combines publication growth (last 24 months vs. prior baseline), trial activity growth, and network proximity to current Tier 1 KOLs. Confidence band reflects data sparsity — narrower for KOLs with longer track records. All sources are public-domain: PubMed, ClinicalTrials.gov, EU CTR, society directories. The score is not a prediction of tier ascent — it is a signal of accelerating relevance.
Decision · DACH hepatology
Gap intelligence
1 active gap detected · scanned against the full DACH hepatology universe
Engagement gap — Prof. Doe (USZ) not on Dr Falk roster
Leading PSC voice at University Hospital Zurich. EASL 2022 PSC guideline co-author. Peer network extends to 10+ Swiss hepatologists. Highest-priority single gap before Q4 2026 SASL annual meeting.
Prof. Dr. med. John Doe · University Hospital Zurich
8.5/10
Scientific output
8.5
weight 35%
Clinical & research
9.0
weight 35%
Influence
8.0
weight 30%
Sources: PubMed · ClinicalTrials.gov · EFPIA · SGG-SSG · SASL · USZ website
Refreshed 2 days ago
nFADP & EFPIA compliant
Geographic · DACH hepatology
Network view
KOLs plotted geographically · co-authorship and committee ties · bridge-builders highlighted in red
Tier 1 KOL
Tier 2 / 3
★ Rising star
Bridge-builder
Co-authorship
Clinical trial
Audit-ready · transparent by design
Methodology
How KOLens scores, sources, and validates every profile · locked to phamax v3 Excel methodology · auditable end-to-end
Scoring formula
3-dimension weighted composite
Each KOL scored 0–10 across three dimensions. Five sub-criteria per dimension scored against a Max value.
Composite =
(Scientific × 0.35) +
(Clinical × 0.35) +
(Influence × 0.30)
(Scientific × 0.35) +
(Clinical × 0.35) +
(Influence × 0.30)
- Default weights · 35 / 35 / 30 — canonical Excel methodology
- Alternative lenses · Scientific rigor (50/35/15) · Medical engagement (25/35/40) · Commercial relevance (20/30/50) — applied per objective
- Tier thresholds · T1 ≥ 7.5 · T2 5.0–7.4 · T3 < 5.0
Evidence confidence
Three-level confidence per profile
Every score is paired with an evidence confidence indicator — visible on roster, profile, and Ask AI responses.
- ●●● High · ≥ 4 evidence types confirmed (publications · trials · congresses · society roles · institution)
- ●●○ Medium · 2–3 evidence types · identity confirmed · limited breadth
- ●○○ Low · < 2 evidence types · manual validation pending
Data sources
All public-domain · source-traceable per data point
- PubMed / Scopus · publications · 5-year window
- ClinicalTrials.gov + EU CTR · trial roles · 3-year window
- EASL / SASL / SGG-SSG · society roles · congress activity · 3-year window
- EFPIA disclosure database · advisory board · payment transparency
- Hospital + university directories · affiliation · dept role · academic position
- Editorial board listings · journal mastheads · impact factor
- phamax Desk Research · manual validation · disambiguation · normalization
Compliance posture
GDPR + nFADP + EFPIA tri-jurisdictional
- GDPR · phamax acts as data processor · Dr Falk Pharma as controller · data minimization principle
- nFADP Art. 19 · Swiss federal data protection · public-source only · no personal contact data stored
- EFPIA Code · advisory board / payment disclosures sourced from public registries · never inferred
- No personal or judgmental data · no photos · no inferred preferences
- Audit trail · every score traceable to source URL + capture date
- Human-in-loop · phamax analyst validates every entry before publication
Why methodology is locked, not editable: Leadership users can switch weight profiles (Default · Scientific rigor · Medical engagement · Commercial relevance) to re-rank against their objective. But the underlying scoring rules, sub-criteria, and source priorities are locked to the phamax v3 Excel methodology — preserving consistency across engagements and audit defensibility for any external reviewer.
Architecture · MCP-ready connector framework
Data connectors
Excel today · API tomorrow · MCP-standard architecture · co-created with you · scales without redesign
KOLens is built on a five-layer architecture: Data input → Connector → Evidence processing → Scoring → Leadership intelligence. The connector layer is where new data sources plug in without restructuring the app. Excel is the MVP input; APIs, document ingestion, and MCP-compatible tools come online phase by phase.
Phase 1
Live
Excel + Desk Research
- Excel upload · phamax v3
- phamax Desk Research
- PubMed (manual)
- ClinicalTrials.gov (manual)
- SGG-SSG · SASL directories
Phase 2
Q3–Q4 2026
API + document ingest
- PubMed API · automated refresh
- ClinicalTrials.gov API
- EU CTR connector
- EFPIA disclosure feed
- Congress programme PDF ingestion
Phase 3
2027
MCP + public-source
- MCP connector framework
- Hospital directory crawler
- University faculty pages
- Editorial board listings
- Guideline document ingestion
Phase 4
2027+
CRM + digital
- Veeva / Salesforce export
- CRM engagement overlay
- DOL / social signal module
- LinkedIn · X public layer
- Patient advocacy registries
The bridge from proposal to platform: the Excel deliverable in your proposal is Phase 1. Phases 2–4 are co-creation territory — phamax invests engineering, Dr Falk co-invests insight on which connectors matter for Swiss hepatology first. MCP is the standardised AI-access layer that lets Ask AI query any approved source without bespoke integration. Every connector goes through compliance review before activation.
← KOL roster
KOL-CH-HEP-0042
Prof. Dr. med. John Doe
Tier 1 Scientific PioneerProfessor of Hepatology · University Hospital Zurich (USZ) · Dept. of Gastroenterology & Hepatology
Overview
Publications
Trials
Activity
Network
Composite score
8.5/10
Tier 1 · Top 10% nationally · Default weights 35/35/30
Dimensions
Scientific output
8.5/10
Clinical & research
9.0/10
Influence & affiliations
8.0/10
Sources
PubMed / Scopus
ClinicalTrials.gov
EASL / SASL
Society websites
USZ website
phamax Desk Research
Data completeness
96%
📄
42
Publications (5yr)
📚
18
PSC-specific
📊
22
H-Index
🔗
~1,240
Citations
🧪
4
PI / Sub-PI trials
🎤
EASL 24
Last congress
⭐
25.7
Top journal IF
Publication trajectory · 2021–2025
First-author · Co-author · Senior-author breakdown
First author
Co-author
Senior author
M
Ask AI · narrative
auto-generated
Since 2021, Prof. Doe has been a part of 42 publications. In the last 3 years, his senior-author share rose from 22% to 48% — signaling shift into senior PI role.
During this phase he was lead author on the EASL 2022 PSC guideline and currently co-chairs the SGG-SSG PSC working group, with the next update due Q3 2026.
Recommended hook for SASL Q4: his J Hepatol senior-author paper on long-term UDCA outcomes in PSC — direct fit with Ursofalk®.
During this phase he was lead author on the EASL 2022 PSC guideline and currently co-chairs the SGG-SSG PSC working group, with the next update due Q3 2026.
Recommended hook for SASL Q4: his J Hepatol senior-author paper on long-term UDCA outcomes in PSC — direct fit with Ursofalk®.
⚑ Key insight — engagement gap
Prof. Doe is not on the current Dr Falk internal KOL list — identified as a significant gap. He is the leading PSC voice at USZ and a co-author on the EASL 2022 PSC guidelines. His peer network extends to 10+ Swiss hepatologists. Recommend prioritisation for scientific engagement prior to next SASL annual meeting (Q4 2026).
⚐ Analyst flags
Data quality
Strong · PubMed, ClinicalTrials.gov, and society directories all current.
Data gap
Advisory board participation not publicly disclosed — EFPIA restriction. Flag, do not infer.
Rising star?
No · established T1 since 2019. Continued senior-author momentum.
Network signal
10+ co-authors in Swiss PSC cluster · strong ties to Basel and Bern.
Compliance
Public sources only · GDPR + nFADP + EFPIA aligned · 0 EFPIA disclosures · 0 Sunshine entries · no personal contact data stored.
Next action
Primary validation call with phamax Medical Affairs before engagement initiation.
Practice context
Pharma-specific signals that H1 and Veeva don't surface for Swiss hepatology
Hospital tier
Tertiary Academic Center
USZ · University Hospital Zurich
Language region
DE · Zürich canton
German-speaking Switzerland
Dept. role
Sr. Attending / Professor
Dept. of Gastroenterology & Hepatology
Open trials
2 recruiting · 4 active
Last updated 5 days ago · ClinicalTrials.gov
KOL scoring & prioritisation
Weight profile
Default35/35/30
Scientific rigor50/35/15
Medical engagement25/35/40
Commercial relevance20/30/50
| Dimension | Weight | Raw (0–10) | Weighted | Score basis |
|---|---|---|---|---|
| Scientific output | 35% | 8.5/10 | 2.98 | Publications · Citations · Guideline authorship Source: PubMed / Scopus |
| Clinical & research leadership | 35% | 9.0/10 | 3.15 | PI/Sub-PI roles · Trial leadership · RWE Source: ClinicalTrials.gov · EU CTR |
| Influence & affiliations | 30% | 8.0/10 | 2.40 | Society roles · Advisory boards · Speaker activity · Editorial boards Source: EASL / SASL / Congress programs |
| Composite | 100% | — | 8.53/10 | Tier 1 · Top 10% nationally |
Commercial relevance
Prescribing profile
High-volume rare hepatology
Estimated patients
~80–120 PSC patients (annual)
Peer influence tier
High — national reference voice
Referring network
~15 affiliated hepatologists
Engagement history
No known Dr Falk contact
Engagement priority
HIGH — gap in current list
Relevant brands
Ursofalk® · (other products)
Institutional pull
USZ protocol setter for PSC
Competitor exposure
[Research pending]
Access route
Via hepatology OPD + MDT referral
Key message fit
Evidence-base · Guideline alignment
Recommended action
Initiate via SASL scientific meeting
Recommended engagement channel
11:1 scientific meeting
→
2Advisory board
→
3Symposium speaker
Ask AI
Your conversational layer over the KOL universe · every answer cites its source · sourced reasoning, not invention
AI
Ask AI
Knows your 13-KOL DACH hepatology universe
Hi Ritu. I track 13 KOLs across Switzerland and Germany in your PSC, PBC and AIH workspace. Ask in natural language — every answer is grounded in the underlying data, every recommendation comes with a "why".
Leadership-grade questions
Benchmark & gap intelligence
Which high-evidence KOLs are missing or under-prioritized in our internal list, and why should leadership review them?
Rising stars · future influence
Which emerging Swiss hepatology voices show early signals of future influence but are not yet visible in the internal list?
Advisory · strategic planning
Which KOLs appear most suitable for strategic advisory input based on scientific footprint, institutional relevance, and society activity?
Evidence confidence · trust
Which recommendations are strongest from an evidence-confidence perspective, and which profiles require human validation before action?
Every response is sourced · audit trail kept for compliance review · GDPR + nFADP + EFPIA